Technology
Biology Technology
Nanowires may boost solar cell efficiency, UC San Diego engineers say
| 5/14/2008 | University of California, San Diego electrical engineers have created experimental solar cells spiked with nanowires that could lead to highly efficient thin-film solar cells of the future. Indium phosphide (InP) nanowires can serve as electron superhighways that carry electrons kicked loo... [Comments] |  |
| 5/14/2008 | This release is available in German . Chinese researchers have recently made a golden crown with a diameter of only a few nanometers. It is a large ring-shaped molecule containing 36 gold atoms. The lords of the ring, a team of researchers from the Universities of Beijing, Hong K... [Comments] |  |
Commencement 2008: Student innovation could improve data storage, magnetic sensors
| 5/14/2008 | Troy, N.Y. Paul Morrow, who will graduate from Rensselaer Polytechnic Institute on May 17, has come a long way from his days as an elementary school student, pulling apart his mothers cassette player. The talented young physicist has developed two innovations that could vastly improve magnetic data storage and sense extremely low level magnetic fields in everything from ink on counterfeit cu... [Comments] |
Micro and Nano Scale Characterization of Fibers
| 5/14/2008 | Fibres present massive challenges and opportunities for micro and nano technologies. These challenges are not in the manufacturing of the fibres but in the control and understanding of their behaviour. This one-day workshop will focus on the many challenges of fibre analysis at the micro and nano-scale using state-of-the art surface chemical analysis, including SIMS, XPS and SPM techniques... [Comments] |
New efficiency record for solar cells
| 5/14/2008 | The efficiency improvement is achieved by the use of an ultra-thin aluminum oxide layer at the front of the cell, and it brings a breakthrough in the use of solar energy a step closer. An improvement of more than 1 per cent (in absolute terms) may at first glance appear modest, but it can enable solar cell manufacturers to greatly increase the performance of their products. This is because... [Comments] |
China Biologic Products Announces First Quarter 2008 Results Conference Call
| 5/14/2008 | TAI'AN CITY, Shandong, China, May 14 /Xinhua--China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP", "theCompany"), one of the leading plasma-based pharmaceutical companies in thePeople's Republic of China ("PRC"), today announced that it will conduct aconference call at 5:00 p.m. Eastern Time on Thursday, May 15, 2008 todiscuss the first quarter 2008 re... [Comments] |
Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
| 5/14/2008 | SOUTH SAN FRANCISCO, Calif., May 14 /- VaxGen,Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, todayprovided guidance on its expected monthly cash expenditures following themost recent restructuring undertaken on April 9, 2008. VaxGen expects thatits average monthly cash expenditures going forward are unlikely to exceed$1 million, made up of the follo... [Comments] |
Oncothyreon to receive milestone payment
| 5/14/2008 | BELLEVUE, WA, May 14 / Oncothyreon Inc. (Nasdaq:ONTY) (TSX: ONY) (the "Company") today announced that it has completed thetransfer of certain assays and manufacturing technology related toStimuvax(R) (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany,triggering a payment to Oncothyreon of $3 million. The payment will be madeunder the terms of the amended... [Comments] |
3SBio Inc. Announces First Quarter 2008 Results
| 5/14/2008 | - Q1 2008 net revenues grew 56.8%, as compared to Q1 2007, to RMB55.5 million (US$7.9 million) - Q1 2008 operating income grew 22.4%, as compared to Q1 2007, to RMB14.2 million (US$2.0 million) - Q1 2008 net income grew 22.3%, as compared to Q1 2007, to RMB 19.8 million (US$2.8 million) SHENYANG, China, May 14 /Xinhua-PR... [Comments] |
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
| 5/14/2008 | SAN DIEGO, May 14 /- Ardea Biosciences, Inc.(Nasdaq: RDEA ) today announced that preclinical data will be presented onthe Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at Digestive Disease Week (DDW) 2008 in San Diego. The oral presentation details are as follows: Date/Time: Tuesday, May 20, 2008 at 3:30 p.m. Pacific Time Abstr... [Comments] |
LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
| 5/14/2008 | LAGUNA HILLS, Calif., May 14 /- LifeStemInternational, Inc., (OTC Bulletin Board: LSTM), formerly CalbaTech, Inc.,an emerging life sciences company concentrating on providing products andplatforms to the research market for biotech and pharmaceutical companiesand to academic institutions, as well as providing services in thecollection, processing and storage of ad... [Comments] |
Medicine Technology
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
| 5/14/2008 | BRISBANE, Australia, May 14 /- ProgenPharmaceuticals Limited (ASX:PGL; Nasdaq: PGLA) today announced that theCompany has resumed patient enrolment in the phase 1 dose-escalation studyof its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047)for patients with advanced cancer. Progen has commenced development of PG-11047 - the lead clinicalcompound... [Comments] |
Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
| 5/14/2008 | CAMBRIDGE, Mass., May 14 /- Biopure Corporation(Nasdaq: BPUR ) today announced that the results from its Phase II coronaryrevascularization trial have been published in the peer-reviewedEuroIntervention Journal. The paper is entitled "Proof-of-concept trial toevaluate haemoglobin based oxygen therapeutics in elective percutaneouscoronary revascularization. Ration... [Comments] |
PacificGMP Completes GMP Product Fill for Trius Therapeutics
| 5/14/2008 | SAN DIEGO, May 14 /- PacificGMP, the leader in utilizingsingle-use bioprocessing for development and manufacturing for its clientpartners, announced today that it has completed a product fill under GMP(good manufacturing practices) standards for a Trius Therapeutics Phase Iclinical trial. "We are pleased to have worked closely with Trius on this GMP fillproject, an effort... [Comments] |
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
| 5/14/2008 | Believed by experts to be important for cervical cancer prevention GRAZ, Austria, May 14 /- New data from anextended follow-up study show that GlaxoSmithKline (NYSE: GSK ) cervicalcancer candidate vaccine, CERVARIX(R) generates sustained high levels ofneutralizing antibodies against the two most common cervical cancer-causinghuman papillomavirus types for up to... [Comments] |
Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
| 5/14/2008 | NEW YORK and WASHINGTON, May 14 /- Revolution Health andEmergingMed today announced that they have teamed up to offer patients andphysicians the largest personalized cancer clinical trial matching andreferral service in the United States. Individuals can quickly assess theireligibility for more than 10,000 clinical trial listings in a confidentialand efficient way through a... [Comments] |
| 5/14/2008 | Data Presented at the American Society of Hypertension's Twenty-Third Annual Scientific Meeting - A cumulative forty-five percent (45%) of patients with stage 1 hypertension treated with a regimen of BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved normotension (< 120/80 mm Hg) (placebo:1.4%). -... [Comments] |
PRoFESS(R) Results Announced at XVII European Stroke Conference
| 5/14/2008 | RIDGEFIELD, Conn., May 14 /- Results of the PRoFESS(R)(Prevention Regimen For Effectively avoiding Second Strokes) trial -- theworld's largest clinical research study for secondary stroke prevention --were presented today at the XVII European Stroke Conference in Nice,France. In the study, recurrent stroke event rates for Aggrenox(R) andclopidogrel were similar (9.0% and 8.... [Comments] |
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
| 5/14/2008 | -Successful Collaboration with Scripps Florida and Scripps Research in La Jolla- SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., May 14 /- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), abiopharmaceutical company focused on oncology, and The Scripps ResearchInstitute, a non-profit biomedical research organization, today announcedt... [Comments] |
| 5/14/2008 | NICE, France, May 14 /- NeurobiologicalTechnologies, Inc. (NTI(R)) (Nasdaq: NTII ) reported for the first time atthe European Stroke Conference detailed analyses supporting the dosingregimen in NTI's two ongoing Phase 3 studies of Viprinex(TM) (ancrod) forischemic stroke. The company also provided information as to why itbelieves these studies are more likely to... [Comments] |
Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
| 5/14/2008 | Recognized clinical trial innovations advocate to lead expansion of Cytel's adaptive trial design and implementation business CAMBRIDGE, Mass., May 14 /- Cytel Inc., a leading providerof clinical trial design services and specialized statistical software,today announced the appointment of Judith Quinlan as Vice President,Adaptive Trials. Judith Quinlan brings over t... [Comments] |
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
| 5/14/2008 | - Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3 treatment-experienced patients - PRINCETON, N.J., May 14 /- Pharmasset, Inc.(Nasdaq: VRUS ) has commenced dosing two additional cohorts of a 4-weekPhase 1 study of R7128 in combination with Pegasys(R) (peg... [Comments] |
(Date:5/14/2008)...rman . ,, Chinese researchers have rece... few nanometers. It is a large ring-shaped molecul... a team of researchers from the Universities of Be... compound in the journal Angewandte Chemie: the mo...y by goldgold bonds and is thus the largest ring s...
(Date:5/14/2008)...ay 14 /Xinhua--,China Biolo...P", "the,Company"), one of the leading plasma-base...c of China ("PRC"), today announced that it will c... on Thursday, May 15, 2008 to,discuss the first qu...onference call, please dial the following,number f...
(Date:5/14/2008)...irstCall/ -- Ardea Biosciences, Inc.,(Nasdaq: RDE...presented on,the Company,s lead mitogen-activated ...Disease Week (DDW) 2008 in San Diego., The oral...ime: Tuesday, May 20, 2008 at 3:30 p.m. Pacific Ti...ly Selective MEK Inhibitor Ameliorates Murin...
(Date:5/14/2008)...re/ -- MEDdevice Acquisition Co., LLC,MDAC is prou...nced team,with deep domain experience and proven s...e market as board members and advisors., Board me...ent Enterprises, LLC, formerly of Vital Signs,Inc....man and CEO of SomaLogic Inc., and formerly of,NeX...
Breaking Biology Technology:Golden nanocrown 2China Biologic Products Announces First Quarter 2008 Results Conference Call 2Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2MEDdevice Acquisition Co., LLC Announces Board Members and Advisors 2...irie , a business-process IT firm active in supply...f pre-configured RFID products for manufacturers. ... containers that can be used to track them. Wal-Ma...iers begin using RFID on all products by this Janu...ext 2006 because of implementation trouble. , ,Oth...
...linton authored a book entitled "It Takes a Villag...d villages of our country surrounding our children...r children. , ,While the primary responsibility of...e extended family (friends, neighbors, teachers an...st in the development of the children. , ,Clinton ...
...e state will give $250,000 in tax credits to C3 Co...build an 18,000-square-foot facility in Appleton,s... Jim Doyle,s office, the $2.4 million project will...of Wisconsin,s Technology Zone Program , which ha...eight zones of the state. , ,Credits are available...
...e, you need to be proactive with networking for it...ffort before you begin to reap the rewards of your...put in some effort to network with you. However, y...rking is not a one-sided process. , Produce Your O...et yourself in front of people is to produce your ...
Other Biology Technology:Creating thousands of jobs, Chicagos biotech space to triple 2Creating thousands of jobs, Chicagos biotech space to triple 3Creating thousands of jobs, Chicagos biotech space to triple 4Creating thousands of jobs, Chicagos biotech space to triple 5Creating thousands of jobs, Chicagos biotech space to triple 6Creating thousands of jobs, Chicagos biotech space to triple 7Creating thousands of jobs, Chicagos biotech space to triple 8Be proactive with networking to make it work for you 2Be proactive with networking to make it work for you 3Be proactive with networking to make it work for you 4(Date:5/13/2008)...ewswire/ -- USHIFU, LLC, the clinical trial,manage...s, IN), is pleased,to announce conditional written...om the FDA to begin a pivotal trial for the treatm...e(R) 500 in men who have failed,external beam radi...ology at NYU School of Medicine and,medical monito...
(Date:5/13/2008)...wswire/ -- New soluble polymer material,designed t...on and healing,according to a new animal study ju...S). The findings come on the heels of recently pub...lymer may lower the risk of,surgical infections., ...Carolina at Charleston,and Keck School of Medicine...
(Date:5/12/2008)...) to acquire Iomai Corporation (,Iomai,) in a, ful... per share of Iomai,s common stock representing ...mately USD 189 million (EUR 122 million). Acquisit...change for approximately 41 percent of Iomai,s cu...s for,approximately 1.7 million Intercell shares (...
(Date:5/12/2008)...re-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin B...velopment,company, announced today that it has ent...ement with Fusion Capital Fund II, LLC, a Chicago-...ll up to $10 million of its common stock to Fusion...after the Securities and,Exchange Commission has d...
Breaking Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3NCCAM expands Centers of Excellence in CAM research program 3041 1NCCAM expands Centers of Excellence in CAM research program 3041 2NCCAM expands Centers of Excellence in CAM research program 3041 3AviaraDx Presents at 2007 BIOCOM Investor Conference 3038 1Governor Rendell Declares Senior Smiles Day in Pennsylvania 3B Goal is to Improve Oral Hygiene for Senior Citizens 3034 1Governor Rendell Declares Senior Smiles Day in Pennsylvania 3B Goal is to Improve Oral Hygiene for Senior Citizens 3034 2Penn biochemist receives NIH New Innovators Award 705 1Penn biochemist receives NIH New Innovators Award 705 2[0] FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer[0] Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows[0] Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation[0] GeoVax Secures $10 Million Financing Commitment
...: 150%; mso-hyphenate: none">,BUDAPEST, Hungary, J...thousands of patients with cancer from suffering,u...h Congress of,the European Association for Palliat...stigated whether this first in class novel,formula...hort,duration of effect, mirroring the breakthroug...
...nt and Phase IIa Daily,Oral Results, LAUSANNE, Swi...,Group (Debiopharm), a global independent biopharm...erious medical conditions,presented final results... treatment of Alzheimer,s disease (AD) at the Alzh...e Prevention of Dementia,in Washington, DC: , - T...
Other Medicine Technology:Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease 2Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |